Benzodiazepine Dependence Is Not Addiction: Why the Labels Are Wrong

Is a person going through benzodiazepine withdrawal addicted to the drug?

Usually, no. The person took a medication the way a doctor prescribed it, often for years, and now cannot stop it without becoming ill. That condition has a name, and the name is physical dependence.

Physical dependence is not addiction. Addiction is a pattern of behavior: taking a drug for the high, taking more than intended, and continuing despite the damage it does. Dependence is a change in the body, and it can happen to anyone who takes a benzodiazepine long enough.

The United States Food and Drug Administration (FDA) said as much in its 2020 boxed-warning update for the benzodiazepine class: physical dependence can develop within days to weeks of steady use, even as prescribed, while abuse and misuse are described separately. Dr. Mark Leeds, an osteopathic physician and deprescribing specialist in Fort Lauderdale, Florida, has built his practice around that distinction.

So, why does the label stick to so many patients, and what does it cost the person who wears it?

What happens in the brain at a prescribed dose.

Benzodiazepines act on gamma-aminobutyric acid (GABA), the brain’s main calming signal. They make the GABA-A receptor respond more strongly to that signal, which is why a dose calms or sedates. Yet, the brain does not leave that arrangement alone.

The Ashton Manual, written by Professor C. Heather Ashton and published at benzo.org.uk, describes the adjustment in Chapter I, in its section on tolerance. With continued use, the GABA and benzodiazepine receptors become less responsive, so the calming action of both the drug and the brain’s own GABA is reduced.

While this is not a perfect analogy, it helps to think of dark sunglasses. Wear them indoors for months and the pupils widen to let in more light, until the room looks normal through the tint. Take them off all at once and daylight is blinding, not because the person is addicted to sunglasses, but because the eyes adapted to them.

The blinding light is withdrawal, and the wide pupils are dependence. Nobody would call that person a “junkie” for squinting, or tell them to stare at the sun until they got used to it. The sensible thing is to lighten the tint a little at a time, and that is what a taper does.

Why is quitting so hard if it is not addiction?

Three things make it hard, and all of them are pharmacology. The first is tolerance. The dose that once worked stops working, and a doctor may raise it. From the outside that can look like a person chasing a drug, when the receptors have simply adjusted again.

The second is interdose withdrawal. Short-acting benzodiazepines such as Xanax (alprazolam) and Ativan (lorazepam) wear off within hours, and Chapter I of the Manual notes that people taking them develop anxiety between doses and an urge for the next one, what Chapter II calls a mini-withdrawal. Watching the clock for the next tablet is what dependence on a short-acting drug feels like from the inside, and what gets mistaken for addiction from the outside.

The third is the withdrawal syndrome itself. The 2020 FDA update reports withdrawal symptoms lasting many months in some patients, and Chapter II of the Manual warns that abrupt or over-rapid withdrawal, especially from a high dose, can cause severe symptoms, including convulsions.

Anyone having a seizure, or any other medical emergency, needs emergency services (911) at once. Anyone having thoughts of suicide can call or text 988, the Suicide and Crisis Lifeline, at any hour.

Chapter I of the Manual calls this pattern therapeutic dose dependence: prescribed, usually low, doses taken for months or years, a gradual need for the drug to get through ordinary daily activities, and difficulty stopping because of withdrawal symptoms. None of it requires a high, or a single broken rule.

The “addict” label sends the patient to the wrong kind of care.

Words decide which door a patient walks through. Once a family member or an emergency doctor says “addict,” the next stop is an addiction treatment program built for a different condition, one driven by compulsion rather than by a prescription. Its tools are a stay of a fixed number of days, group meetings, support-group programs, and a goal of being drug free by discharge.

None of those tools reaches a GABA receptor. The program’s calendar sets the pace, not the patient’s nervous system, so a taper that should take months is squeezed into days. In that setting, the diagnosis has a way of matching whichever bed is available.

Unfortunately, the result is the abrupt or over-rapid withdrawal that the Manual warns against. The patient goes home shaking, sleepless and in pain, and the illness the program caused is written up as proof that the diagnosis was right all along.

People who do have an addiction deserve dignity and good care, and there is no shame in needing it. The point is not that those programs are wrong for everyone. It is that they treat a condition this patient does not have.

The words themselves do harm.

“Junkie” is a slur, and “addict” is a label that turns a person into a diagnosis. Person-first language exists for a reason. A person with an addiction is a person first, and a person with benzodiazepine dependence is a patient with a condition that a prescription caused.

The label follows the patient into every waiting room, where pain gets dismissed as drug-seeking and a request for a slower taper gets read as manipulation. And, it gets inside the patient, who starts to believe they did something wrong by taking a pill exactly as directed.

Shame is expensive. It keeps people from asking for help with a taper, and it pushes some of them to quit on their own, all at once, the most dangerous way to stop. Even when an addiction really is present alongside the dependence, the dependence still needs a gradual medical taper and is never dismissed as part of the addiction.

What a gradual taper looks like instead.

A taper is the slow lightening of the tint. Chapter II of the Ashton Manual suggests reducing by up to one tenth of the current dose at each step, and it states that the rate is an individual matter and that the patient is the best judge of the pace. Dr. Leeds does not publish a schedule, because the pace belongs to the person taking the drug, worked out with their prescriber.

The shape matters more than any number. The Maudsley Deprescribing Guidelines describe hyperbolic reductions, in which each cut is a fraction of the dose that remains, so the steps shrink as the dose falls. The last small amounts do the most work at the receptor, so the end of a taper needs the gentlest touch.

Holds are part of the plan, not a failure of it. When a step brings on a wave of symptoms, the dose is held until the person feels steady, and then the taper resumes. The usual scale is months, sometimes longer, and in Dr. Leeds’ medically supervised benzodiazepine tapering the patient directs that pace.

When does a crossover taper to diazepam help?

Short-acting benzodiazepines are awkward to taper directly. Their blood levels rise and fall several times a day, and every trough is a mini-withdrawal. Chapter II of the Manual, with the equivalence table in Chapter I, gives the answer: a crossover taper, in which the short-acting drug is replaced in stages by an equivalent dose of Valium (diazepam).

Diazepam leaves the body slowly, over days rather than hours, so its level barely moves between doses and the interdose swings settle. It also comes in small, scored tablets, which allows very small reductions near the end. Dr. Leeds applies the Ashton Manual this way: the crossover taper where it helps, and a direct taper where that is going smoothly.

What he never recommends is stopping abruptly. Professor Ashton wrote that the one exception to slow reduction, in her experience, was Halcion (triazolam), a drug eliminated so quickly that the body is nearly withdrawn from it each day, which she said could be stopped without substitution. Dr. Leeds still prefers a gradual taper even there, in line with the boxed warning on every benzodiazepine label, which calls for a gradual taper when reducing or discontinuing the drug.

Dr. Leeds’ practice treats dependence as the medical condition it is.

Every taper in Dr. Leeds’ practice begins with informed consent: the risks first, the alternatives, including staying at the current dose for now, an exit plan from the first visit, and the right to decline or pause at any point. There are no meetings to attend and no program to complete. There is one physician, one patient, and a plan that bends when the patient’s symptoms say it should.

Patients who have been called an “addict” by a hospital or their own family often arrive expecting to be judged again. What they find is a doctor who reads their history as prescribed dependence and treats it that way. Fortunately, the body that adapted to the drug can adapt back, given enough time and a gentle enough slope.

Dr. Leeds’ practice provides medically supervised benzodiazepine and z-drug tapering to patients in Florida, from his Fort Lauderdale office and by telemedicine, one patient at a time. Contact Dr. Leeds to discuss a gradual, patient-directed taper.

This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.